MoonLake Immunotherapeutics (Class A) (MLTX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, MoonLake Immunotherapeutics (Class A) (NASDAQ: MLTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.78 (-6.28% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MLTX ranks #630 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MLTX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JANX (Janux Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -13.8%, cap $1.09B) and LTGO (Latigo Biotherapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $1.03B). Among the 5-stock peer group, MLTX leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).
Per MLTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821586), MoonLake Immunotherapeutics (Class A) generated $0 in revenue, -$227.3M in net income, and -$196.0M in free cash flow against $424.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MLTX currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.46) and Max Pain ($12.37) forces dealer call-delta covering toward $24.45.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
MoonLake Immunotherapeutics (Class A) (MLTX) dropped -6.28% to $11.78, trading at 17% of its 52-week range ($9.46 – $23.29). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23.
Key TakeawaysMoonLake shares jumped 18% today after AbbVie reported Phase 3 results for a rival hidradenitis suppurativa drug. AbbVie’s lutikizumab beat placebo by 8 percentage points on its main goal, a result RBC Capit
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MLTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MLTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, MoonLake Immunotherapeutics (Class A) (MLTX) ranks #630 by composite RQD confidence (36/100, grade D-) and #356 by equity capitalization ($1.07B). Within this direct 5-issuer industry benchmark cohort, MLTX leads on earnings valuation at N/A trailing P/E, while HROW leads on capital efficiency and profitability with 42.9% ROIC and 75.1% gross margin. CTY currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with MLTX at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MLTX
ACTIVE
MoonLake Immunotherapeutics (Class A) | D- | 36/100 | — | — | -35.0% | -6.28% | $1.07B | Benchmark Subject |
| JANX Janux Therapeutics Inc. | D- | 41/100 | — | — | -13.8% | -2.02% | $1.09B | /janx-vs-mltx → |
| LTGO Latigo Biotherapeutics Inc. | D- | 43/100 | — | — | — | -10.23% | $1.03B | /ltgo-vs-mltx → |
| CTY City Therapeutics Inc. | C- | 60/100 | — | — | — | -6.46% | $1.11B | /cty-vs-mltx → |
| HROW Harrow Inc. | D+ | 55/100 | — | 75.1% | 42.9% | -5.83% | $1.12B | /hrow-vs-mltx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), MoonLake Immunotherapeutics (Class A) (MLTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$227.3M, operating cash flow of -$196.0M, and free cash flow of -$196.0M (-67.4% YoY). On the balance sheet, MLTX closed FY2025 with $424.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$227.3M | -$196.0M | -$196.0M | $424.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$118.9M | -$116.6M | -$117.1M | $477.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$36.0M | -$42.8M | -$42.8M | — | — |
As of 2026-11-02, MoonLake Immunotherapeutics (Class A) (NASDAQ: MLTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.78 (-6.28% 1D, market cap $1.07B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MLTX ranks #630 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MLTX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JANX (Janux Therapeutics Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -13.8%, cap $1.09B) and LTGO (Latigo Biotherapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $1.03B). Among the 5-stock peer group, MLTX leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).
Per MLTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001821586), MoonLake Immunotherapeutics (Class A) generated $0 in revenue, -$227.3M in net income, and -$196.0M in free cash flow against $424.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MLTX last traded at $11.78 (-6.28% on volume of 1,128,558 shares), positioning the stock -5.46% below its 50-day simple moving average ($12.46) and -28.39% below its 200-day simple moving average ($16.45). Across its 52-week range of $9.46 to $23.29, MLTX sits at the 16.8% percentile with a 14-day RSI of 57.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($10.31 to $13.25).
Why MLTX Stock dropped -6.28% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, MLTX scores 36 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
For a prospective investor evaluating the stock today, the implication is that the rating frames MLTX as a high-risk, cash-consuming company whose balance sheet is serviceable but not strong, with limited insider conviction and negative free cash flow. Upside drivers would need to come from outside the reported cash engine. The valuation tradeoff is that the market cap of $1.07B is being carried by expectations, since the reported fundamentals do not show earnings or cash generation to anchor it.
MoonLake Immunotherapeutics (Class A) (MLTX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it operates with a market capitalization of $1.1B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each period shown, so the source data does not identify a current revenue-generating product line.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-244.8M | $-227.3M | N/A | $-196.0M | $334.5M | N/A |
| FY 2024 | $0.0M | $-143.1M | $-118.9M | N/A | $-117.1M | $180.4M | N/A |
| FY 2023 | $0.0M | $-54.1M | $-36.0M | N/A | $-42.8M | N/A | N/A |
Per the SEC financials, operating and net losses widened each year from FY 2023 through FY 2025, and free cash flow was negative in every period shown. Gross, operating, and net margins are each reported as 0% in the market data, consistent with no reported revenue. Per the market data, ROIC is -35% and FCF yield is -18.33%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2 of 9, and Debt/Equity is 0.5. Reported cash rose from $180.4M to $334.5M between FY 2024 and FY 2025 while losses continued, and debt is listed as N/A in the period data.
The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals. Watch items are the pending FDA priority review decision and the investor day, since the source data presents them as the primary forward catalysts.
Real-time company headlines, analyst actions, and sector developments for MoonLake Immunotherapeutics (Class A) (MLTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering MoonLake Immunotherapeutics (Class A) (MLTX) market action, institutional positioning, and fundamental catalysts.
Welcome to the MLTX (MoonLake Immunotherapeutics (Class A)) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on MLTX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless MoonLake Immunotherapeutics (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on MLTX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $12.57 (52-wk range $9.46 - $23.29), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).